中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:167 更新时间:2025-04-04
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!通过在本页面挂载中生北控BioSino品牌的产品链接和联系邮箱,可以提高中生北控BioSino产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

美国2月贸易逆差1227亿美元

美国商务部普查局4月3日发布数据,2月贸易逆差1227亿美元,预估为逆差1235亿美元,前值为逆差1314亿美元。(界面)

2小时前

美股大型科技股盘前普跌,苹果跌超7%

36氪获悉,美股大型科技股盘前普跌,截至发稿,苹果、亚马逊跌超7%,特斯拉、Arm、英伟达跌超6%,Meta跌超5%,谷歌跌超4%,微软、奈飞跌超3%。

2小时前

热门中概股美股盘前普跌,拼多多跌超6%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超6%,京东跌超5%,百度、爱奇艺、阿里巴巴、B站、蔚来跌超3%,理想汽车跌超2%,网易、腾讯音乐、微博跌超1%。

2小时前

高测股份:控股股东张顼拟询价转让4.99%股份

36氪获悉,高测股份公告,公司控股股东张顼计划通过询价转让方式转让27,308,000股,占公司总股本的4.99%,转让原因为自身资金需求。出让方声明所持股份权属清晰,不存在限制或禁止转让情形,且不违反相关减持规定和承诺。本次询价转让的受让方需为具备相应定价能力和风险承受能力的机构投资者。本次询价转让的价格下限不低于发送认购邀请书之日(即2025年4月3日)前20个交易日高测股份股票交易均价的70%。

2小时前

欧盟成员国拟表决对美关税反制措施

欧盟高级官员4月3日表示,欧盟成员国计划9日投票表决针对美方25%钢铝关税的反制措施。欧盟委员会负责贸易和经济安全等事务的委员马罗什·谢夫乔维奇表示,不合理的关税最终只会适得其反,欧盟将以冷静、有步骤且团结一致的方式作出回应。(新华社)

2小时前

本页详细列出关于康成生物的品牌信息,含品牌所属公司介绍,康成生物所处行业的品牌地位及优势。
咨询